MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...

Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Afqlir (aflibercept) 2 mg vial kit and ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity M ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients d ...

Dr Menon believes that lifestyle modifications are “essential in managing diabetes and preventing complications.” His ...

Clearside Biomedical Inc (CLSD) advances its wet AMD program with positive trial outcomes, while navigating financial and ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

The Korea Research Institute of Standards and Science (KRISS) announced that they have developed an advanced disease ...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine ...